Sudeep Pharma (SUDEEPPHRM) Q2 25/26 earnings summary

Executive summary

• Achieved successful IPO listing on BSE and NSE in November 2025, marking a significant milestone in corporate growth.

• Demonstrated robust H1 FY26 performance, driven by sustained demand, higher volumes, and strong segment results.

• Acquired 85% stake in Nutrition Supplies Services (NSS), enhancing advanced formulation capabilities and global reach.

• Initiated greenfield expansion and entered battery materials segment, leveraging mineral chemistry expertise.

• Converted 14,118,712 CCPS into equity shares, increasing total equity shares to 111,346,602.

Financial highlights

• H1 FY26 total income rose 31% year-over-year to ₹302.9 Cr; Q2 FY26 income up 15% YoY.

• H1 FY26 EBITDA increased 21% YoY to ₹114.7 Cr, with margin at 37.9%.

• H1 FY26 PAT grew 19% YoY to ₹78.0 Cr, with PAT margin at 25.8%.

• Basic and diluted EPS for H1 FY26 at ₹7.05, restated for increased equity shares.

• Cash and cash equivalents increased to ₹5,198.89 lakhs as of 30 September 2025.

Outlook and guidance

• Greenfield facility at Nandesari (51,200 MT annual capacity) on track for Q4 FY26 commissioning.

• Battery-grade iron phosphate manufacturing to serve EV and energy storage markets, leveraging global supply chain shifts.

• Final purchase price allocation for the NSS acquisition is pending and may impact future results.

• The company is evaluating the impact of new Indian labour codes on its business and operations.

• Expect stronger H2 FY26 performance as investments and acquisitions begin to reflect in financials.